Press releaseBusiness Wire
enGene Therapeutics
ENGN · NASDAQ
$1.67+$0.09 (+5.70%)TodayMarket closed ·
Prev close $1.58
Latest news
- Press releaseBusiness Wire
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
enGene to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
- News
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
- Press releaseBusiness Wire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
- Press releaseBusiness Wire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
- Press releaseBusiness Wire
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
- NewsAvi Kapoor
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
US Stocks Mixed; Dow Falls Over 100 Points
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseBusiness Wire
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
- Press releaseBusiness Wire
enGene Announces Name Change to enGene Therapeutics Inc.
- Press releasePRNewswire
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
- Press releaseBusiness Wire
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
enGene to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
- Press releaseBusiness Wire
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
- Press releaseBusiness Wire
enGene Reports Full Year 2025 Financial Results and Provides Business Update
- Press releaseBusiness Wire
enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
- Press releaseBusiness Wire
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseBusiness Wire
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
- Press releaseBusiness Wire
enGene Announces Proposed Public Offering of Common Shares
- NewsAvi Kapoor
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.